Sujets)
Adulte , Femelle , Humains , Antidépresseurs de seconde génération/usage thérapeutique , Antidépresseurs tricycliques/usage thérapeutique , Cyclohexanols/usage thérapeutique , Trouble dépressif majeur/traitement médicamenteux , Trouble dysthymique/traitement médicamenteux , Miansérine/analogues et dérivés , Trouble dépressif majeur/complications , Association de médicaments , Trouble dysthymique/complications , Miansérine/usage thérapeutiqueRésumé
Amisulpride, belonging to second generation antipsychotics, is a substituted benzamide derivative indicated for the treatment of acute and chronic schizophrenia with prominent positive and/or negative symptoms. Amisulpride has high affinity for the dopamine D2/D3 receptors. It inhibits dopamine transmission by blocking postsynaptic D2/D3 receptors in the limbic system, which is predicative of potent antipsychotic activity. The elimination half-life is 12 hours. Metabolism is limited with most of the drug excreted unchanged in the feces (64%). Clinical studies have supported that Amisulpride (400-1200mg/day) is at least as effective as Haloperidol and Risperidone and more effective than flupenthixol in acute exacerbation. In the treatment of patients with predominantly negative symptoms, Amisulpride was more effective than placebo. Recently some studies have shown it to be having efficacy in dysthymia also. Its favorable characteristics also include low incidence of EPSE and weight gain, however, it has a high incidence of prolactin elevation.
Sujets)
Trouble dysthymique/traitement médicamenteux , Humains , Schizophrénie/traitement médicamenteux , Sulpiride/administration et posologie , Sulpiride/effets indésirables , Sulpiride/analogues et dérivés , Sulpiride/pharmacologie , Sulpiride/pharmacocinétiqueRésumé
En el presente artículo se describen las diferentes drogas utilizadas para el tratamiento de la depresión, sus modos de acción, sus efectos adversos y las diversas precauciones y advertencias